If they have finished phase I trials why haven’t they made an announcement? They could at least inform the ASX and shareholders that they are doing the statistical number crunching before officially releasing the results.
The reporter asked if ATH has looked at other applications for PBT 434 with the reply being absolutely. No detail in the response and certainly no mention of PBT2 and it’s usefulness in possible prevention of antibiotic resistance bacteria.
Should not surprise at ATH’s continued lack of respect and information flow for the average shareholder.
Phase1 finished, page-3
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $1.633K | 487.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 32189472 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126368541 | 15 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |